Takara BioFRA:TF2 71 ROA % is 0.06% as of Mar. 2026, which is 99% below its 10-year median of 4.34. GuruFocus rates FRA:TF2 with a GF Score™ of 71/100 and a GF Value™ of €4.46 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,422 Biotechnology companies, Takara Bio ranks better than 72.36% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Takara Bio's annualizedNet Income for the quarter that ended in Mar. 2026 was €0.4 Mil.
Takara Bio's average Total Assets over the quarter that ended in Mar. 2026 was €721.6 Mil. Therefore, Takara Bio's annualized ROA % for the quarter that ended in Mar. 2026 was 0.06%.
The historical rank and industry rank for Takara Bio's ROA % or its related term are showing as below:
FRA:TF2'
s ROA % Range Over the Past 10 Years
Min: -7.41 Med: 4.34 Max: 19.32
Current: -7.37
During the past 13 years, Takara Bio's highest ROA % was 19.32%. The lowest was -7.41%. And the median was 4.34%.
FRA:TF2's ROA % is ranked better than 72.36% of 1422
companies
in the Biotechnology industry
Industry Median: -32.87
vs FRA:TF2: -7.37
Takara Bio (FRA:TF2) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Takara Bio ROA % Related Terms
Takara Bio ROA % Historical Data
* Premium members only.
The historical data trend for Takara Bio's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Takara Bio's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's ROA % distribution charts can be found below:
* The bar in red indicates where Takara Bio's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Takara Bio (FRA:TF2) has a ROA % of 0.06% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Takara Bio and its competitors. This is 99% below median its historical median of 4.34. According to the industry distribution chart, Takara Bio ranks #393 out of 1422 companies in the Biotechnology industry, placing it in the top 27.6%.
Is Takara Bio's ROA % too high?
Takara Bio's current ROA % of 0.06% is 99% below median its 10-year median of 4.34. Based on the distribution chart, Takara Bio ranks #393 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Takara Bio has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #393 out of 1422 companies for ROA %. This puts Takara Bio in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Takara Bio and its competitors. Takara Bio's current ROA % is 0.06%, which is 99% below median its own 10-year median of 4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.46, compared to a current price of €5.95 — trading 33.4% above its estimated fair value. The current ROA % is 0.06%, which is 99% below median its 10-year median of 4.34. Takara Bio's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current ROA % is 0.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 33.4% above its estimated GF Value™ of €4.46.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
ROA %: 0.06% (99% below median its 10-year median of 4.34)
GF Value™: €4.46 vs. price of €5.95 (33.4% above fair value)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
71GF Score
Get the complete analysis for FRA:TF2
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
